July 2022 in “Media Dermato Venereologica Indonesiana” The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
January 2007 in “Yearbook of Dermatology and Dermatologic Surgery” Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.
August 2023 in “Clinical and Experimental Dermatology” The document discusses a special exam case for formulating and using systemic therapy named Athena.
June 2023 in “British Journal of Dermatology” The prototype for analyzing skin aging works technically and clinically.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
January 2024 in “Archives of dermatological research” Both treatments for alopecia areata showed similar modest effectiveness.
January 2026 in “JAAD International” Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
5 citations
,
July 2019 in “Applied statistics/Journal of the Royal Statistical Society. Series C, Applied statistics” Case-only trees and random forests improve predictions of treatment effects in clinical trials.
1 citations
,
January 2024 in “Journal of Cutaneous and Aesthetic Surgery” Fractional CO2 laser with topical triamcinolone is more effective and safer for treating alopecia areata than intralesional triamcinolone.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
21 citations
,
December 2014 in “Clinics in dermatology” Squaric acid dibutylester effectively treats alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
66 citations
,
July 2003 in “International Journal of Dermatology” Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
January 2026 in “The FASEB Journal” The trial aims to test a new treatment for hair loss in young men using stem cell-derived vesicles.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
February 2023 in “Research Square (Research Square)” Autologous Cellular Micrografts effectively treat hair loss with significant improvements and no dangerous side effects.
July 2022 in “British Journal of Dermatology” July 2025 in “Journal of Investigative Dermatology” December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.